CSL Opens World-Class, Advanced Manufacturing Facility for Late-Stage Production of Hemophilia Therapies Now in Development

    CSL Opens World-Class, Advanced Manufacturing Facility for Late-Stage
            Production of Hemophilia Therapies Now in Development

-- Leading-edge science at the core of $250 million expansion to drive
long-term growth in promising bleeding disorders portfolio

-- CSL Behring to commercialize therapies produced in part at the facility,
pending required approvals

-- Opening taking place in advance of World Federation of Hemophilia 2014
Congress in Melbourne, Australia

PR Newswire

KING OF PRUSSIA, Pa., May 9, 2014

KING OF PRUSSIA, Pa., May 9, 2014 /PRNewswire/ --CSL Limited (ASX:CSL),
parent company of CSL Behring which is based in King of Prussia, PA, today
opened the CSL Behring Biotechnology Manufacturing Facility in Melbourne,
Australia. The new facility, located adjacent to the site's manufacturing
plant for plasma products, is the centerpiece of CSL's $250 million expansion
at its Broadmeadows site and will play an increasingly important role in the
company's global operations, particularly in the late-stage development of new
types of hemophilia products. It is one of the largest and most advanced
facilities of its kind in the world and will produce novel recombinant
therapies on a large scale for international clinical trials.

CSL Behring's new biotechnology manufacturing facility in Melbourne,
Australia. It is one of the largest and most advanced facilities of its kind
in the world and will produce novel recombinant therapies on a large scale for
international clinical trials.

"This world-class facility is key to the ongoing success of our global R&D
strategy and reflects our commitment to providing better treatment options for
people who are managing certain bleeding disorders and other life-threatening
conditions," said CSL Chief Executive Officer, Paul Perreault. 

The company's recombinant factor development programs, which comprise the
AFFINITY trial and the PROLONG trial for the study of therapies to treat
hemophilia A and B, respectively, are central to its long-term growth plans.
Several candidates in these trials are showing promise, including
rVIII-SingleChain, rIX-FP, and rVIIa-FP.

Recombinant therapies are modified versions of naturally occurring human
proteins that have been optimized to provide additional treatment options for
patients. CSL has more recently developed specialist capabilities in
recombinant-based research, adding to its long-standing expertise in plasma
protein therapeutics.CSL's research and development pipeline currently
includes recombinant therapies for a range of rare and serious disease,
including bleeding disorders, inflammatory conditions and cancer.

The first therapy to be manufactured in the new Broadmeadows facility will be
a novel blood clotting factor (rVIIa-FP) for the treatment of hemophilia.
This is one of several longer-acting clotting factors under development by CSL
that aims to reduce the number of injections required to maintain normal blood
clotting in people with bleeding disorders. Clinical trials of rVIIa-FP in
patients are expected to commence later this year in the United States, Europe
and Australia. International recruitment is ongoing for the rVIII-SingleChain
and rIX-FP studies.

About CSL

The CSL Group, headquartered in Melbourne, Australia, has a combined heritage
of outstanding contribution to medicine and human health with more than 90
years of experience in the development and manufacture of vaccines and plasma
protein biotherapies. With major facilities in Australia, Germany, Switzerland
and the U.S., CSL has about 12,000 employees in nearly 30 countries.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed
to saving lives and improving the quality of life for people with rare and
serious diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders
including hemophilia and von Willebrand disease, primary immune deficiencies,
hereditary angioedema and inherited respiratory disease, and neurological
disorders in certain markets. The company's products are also used in cardiac
surgery, organ transplantation, burn treatment and to prevent hemolytic
disease in the newborn. CSL Behring operates one of the world's largest plasma
collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited
(ASX:CSL). For more information, visit www.cslbehring.com.

CSL Behring logo.

Photo - http://photos.prnewswire.com/prnh/20140508/86053

Logo- http://photos.prnewswire.com/prnh/20100914/PH63692LOGO

SOURCE CSL Behring

Website: http://www.cslbehring.com
Contact: Christopher Florentz, 610-878-4316,
christopher.florentz@cslbehring.com; Greg Healy, 610-878-4841,
Greg.Healy@cslbehring.com
 
Press spacebar to pause and continue. Press esc to stop.